In addition, PEG IFN has other recognized therapeutic applications, such as in melanoma [21], chronic myeloid leukaemia [22], and renal carcinomas [23]. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.